Canadian Task Force on Preventive Health Care

Screening for type 2 diabetes mellitus to prevent vascular complications: updated recommendations from the Canadian Task Force on Preventive Health Care

2005NationalCMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne

Canada

Read the PDF Original at the sourceAsk Osler about this guideline

Read the guideline

Full guideline, as published128 KBOpen in a new tab Download

Source and rights

Published by CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2005. The PDF is shown as published and remains the work of its authors and publisher; the original is at the source linked here. Rights holders can ask us to remove a file at info@prognia.nl.

Ask a question about this guideline.

Osler answers from this library and names the guideline behind every claim.

Discover Osler

pmc.ncbi.nlm.nih.gov/articles/PMC543976/

Prognia summarises this guideline for reference and education. It is not medical advice. Always check the official guideline and current local protocols before acting on it.

At a glance

Organisation: Canadian Task Force on Preventive Health Care
Published: 2005
Applies to: 🇨🇦 Canada
Scope: National
Journal: CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne
DOI: 10.1503/cmaj.1041197
PubMed: 15655234
PubMed Central: PMC543976
Added to Prognia: 23 July 2026

Who and how to screen for Cushing's syndrome: the position statement of the Italian Society of EndocrinologyWorld Health Organization · 2026Added 23 Jul 2026

Diabetes technology (Update 2026)Wiener klinische Wochenschrift · 2026Added 23 Jul 2026PDF

ISPAD Position Statement on Type 1 Diabetes in SchoolsInternational Society for Pediatric and Adolescent Diabetes · 2026Added 18 Jul 2026PDF

SICOB Italian Clinical Practice GRADE-based guidelines for the endobariatric treatment of overweight, obesity, and obesity-associated diseasesUpdates in surgery · 2026Added 18 Jul 2026PDF

Part 2: CAR Metabolic Dysfunction-Associated Steatotic Liver Disease Working Group Recommendations for Risk Stratifying Patients With MASLD.Dysfunction-Associated Steatotic Liver Disease Working Group · 2026Added 18 Jul 2026PDF

Part 3: CAR Metabolic Dysfunction-Associated Steatotic Liver Disease Working Group Recommendations for Ultrasound Shear Wave Elastography and MR Elastography Program Implementation, Funding, and Quality AssuranceDysfunction-Associated Steatotic Liver Disease Working Group · 2026Added 18 Jul 2026PDF

Part 1: CAR Metabolic Dysfunction-Associated Steatotic Liver Disease Working Group Guidance Statements for Detecting and Grading Hepatic Steatosis Using Ultrasound, CT, or MRI.Dysfunction-Associated Steatotic Liver Disease Working Group · 2026Added 18 Jul 2026PDF

Japan Endocrine Society Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma 2025Endocrine Society · 2026Added 18 Jul 2026PDF

European Association for the Study of Obesity Position Statement on the Diagnosis and Management of Obesity in Older AdultsObesity facts · 2026Added 18 Jul 2026PDF

10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026American Diabetes Association · 2026Added 18 Jul 2026PDF